What is Treatment-Resistant Depression?
Treatment-resistant depression (TRD) is defined as depression that hasn't adequately responded to at least two different medication trials of adequate dose and duration. Similarly, treatment-resistant OCD refers to OCD that hasn't responded sufficiently to traditional treatments.
You're not alone: About 30% of people with depression don't respond adequately to first-line treatments. This doesn't mean you're "broken" or that nothing will work—it means you may need a different approach.
The landmark STAR*D trial showed diminishing returns with each medication attempt—which is why alternative approaches like TMS and ketamine are so important for those who haven't found relief with medication alone.
Take our assessment → to see if you might have treatment-resistant depression.
What is TMS?
Transcranial Magnetic Stimulation (TMS) uses an electromagnetic coil placed against the scalp to deliver focused magnetic pulses. These pulses pass painlessly through the skull and induce small electrical currents in targeted brain regions.
The target: For depression, TMS typically targets the left dorsolateral prefrontal cortex (DLPFC)—a region involved in executive function, decision-making, and emotional regulation. In depression and OCD, this area is often underactive, leading to reduced control over the limbic system (the brain's emotional center).
The goal: By repeatedly stimulating the prefrontal cortex, TMS helps strengthen neural circuits that regulate mood and reduce the overactivity of limbic regions associated with rumination, negative thinking, and compulsive behaviors. In essence, we're helping the brain regain executive control over emotional responses.
Unlike medication, TMS works directly on brain circuits without entering your bloodstream. There's no anesthesia required, no systemic side effects like weight gain or sexual dysfunction, and you can drive yourself to and from appointments.
TMS was FDA-cleared for treatment-resistant depression in 2008 and for OCD in 2018, with additional protocols approved since.
TMS Evidence & Research
Historical Context
The Pivotal Trial: The O'Reardon et al. (2007) study that led to FDA approval showed modest but significant results: 24% response vs 12% sham (MADRS) and 24.5% vs 13.7% (HAMD). While these numbers may seem low, they established TMS as a viable treatment for patients who had failed multiple medications.
Modern Outcomes
Since then, advances in coil design, targeting methods, and accelerated protocols have substantially improved outcomes. Modern accelerated protocols have shown 80%+ response rates. For OCD, studies show significant symptom reduction in treatment-resistant cases.
Why TMS works differently
The STAR*D trial showed diminishing returns with each medication attempt. TMS offers a different mechanism—directly stimulating brain circuits involved in mood regulation rather than altering neurochemistry systemically.
Durability
Effects typically last 6-12 months, with maintenance sessions available if needed.
Our Patient Outcomes
Real results from patients treated at Integrative Mind. These results are numerically higher than those seen in the original FDA approval studies, driven by improvements in protocols and technology over the past 15+ years.
TMS Treatment Protocols
Standard Protocol (6-8 weeks)
- Treatment schedule: Daily sessions (Monday–Friday) for 7–8 weeks
- Session duration: 20–25 minutes
- Total sessions: Typically 36 sessions
- Where: In-office treatment—no anesthesia, you can drive yourself
Most patients begin to notice improvements around weeks 3–4.
Accelerated Protocol (2 weeks)
Multiple sessions per day over 2 weeks. FDA-cleared and shown to be non-inferior to the standard 6-week protocol.
- 87.8% response rate at week 6 (comparable to standard protocol)
- Faster remission—median 21 days vs 28 days for standard
Treatment Schedule Comparison
Response Rates (RCT, n=104)
Remission Rates
Faster Onset of Remission
5-Day Intensive Protocol
Based on the Stanford SAINT protocol research, this intensive approach delivers 50 sessions over 5 consecutive days.
- Treatment schedule: 10 sessions per day for 5 days
- Session spacing: Sessions spaced ~50 minutes apart
- Daily commitment: 8-10 hours per day
- Research: Stanford SAINT study showed 79% remission rates
This protocol requires 5 full days of availability and is typically not covered by insurance.
ONE-D Protocol (Single Day)
The ONE-D Protocol (Optimized Neuroplastogen-Enhanced, single-Day) delivers a full course of TMS treatment in just one day, using techniques that enhance the brain's natural plasticity.
- 93% response rate on clinician-rated depression scale (HDRS-17)
- 78% remission rate—most patients achieved minimal symptoms
- Improvements sustained through 12-week follow-up
ONE-D: Response Rates (Vaughn et al. 2025, n=32)
ONE-D: Remission Rates
Important: The ONE-D protocol is a newer approach and is not covered by insurance. It requires a full day commitment (8+ hours) and uses off-label neuroplastogen agents.
Cost consideration: The ONE-D protocol involves 20 treatment sessions in a single day, compared to 36 sessions in the standard protocol or 50 sessions in the 5-day intensive. This reduced session count may result in lower overall treatment costs.
Ketamine-Assisted Psychotherapy (KAP)
Ketamine represents a fundamentally different approach to treating depression. Unlike traditional antidepressants that take weeks to work, ketamine can produce rapid antidepressant effects within hours.
Mechanism: Ketamine works on glutamate/NMDA receptors—a completely different pathway than traditional antidepressants. This triggers a cascade that promotes rapid synaptogenesis (new neural connections), essentially helping the brain rewire itself.
Landmark Research
Zarate et al. (2006) — Archives of General Psychiatry
The landmark NIH study that established ketamine's rapid antidepressant effects. In this double-blind, placebo-controlled crossover trial, 71% of patients with TRD responded within 24 hours of a single IV ketamine infusion.
PubMed →Murrough et al. (2013) — American Journal of Psychiatry
Larger RCT (n=73) comparing ketamine to midazolam. 64% response rate with ketamine vs 28% with placebo at 24 hours.
PubMed →Fava et al. (2020) — JAMA Psychiatry
Large trial (n=346) showing esketamine nasal spray plus oral antidepressant was superior to antidepressant alone for TRD, supporting the FDA approval of Spravato.
PubMed →Why Ketamine-Assisted Psychotherapy (KAP)? The neuroplasticity window created by ketamine—when the brain is most capable of forming new connections—is an ideal time for therapeutic work. Integrating psychotherapy with ketamine treatment can help translate transient relief into lasting change.
Our Approach: Safety & Supervision
We do not prescribe ketamine for at-home use. All ketamine sessions are conducted in-office under direct medical supervision, integrated with psychotherapy.
- Maximizes safety — continuous monitoring during sessions
- Enhances durability — therapy during the neuroplasticity window helps create lasting change
- Ensures ethical care — no risk of misuse or diversion
Other Options: ECT
ECT (Electroconvulsive Therapy)
The most effective treatment for severe, treatment-resistant depression with 60-80% response rates. Performed under anesthesia. Modern ECT has improved significantly—memory side effects are typically temporary. Often considered when other treatments haven't worked.
Integrative Mind offers TMS and KAP, and can assist with referrals for ECT if appropriate for your situation.
Side Effects
TMS Side Effects
TMS is generally well-tolerated. The most common side effects are:
- Mild headache — usually resolves within hours, most common in first few sessions
- Scalp discomfort — at the treatment site during stimulation, typically diminishes over time
- Fatigue — some patients feel tired after sessions
What TMS doesn't cause: Unlike medications, TMS does not cause weight gain, sexual dysfunction, emotional blunting, or GI issues. It's non-systemic—it works directly on brain circuits.
KAP Side Effects
During ketamine sessions, patients may experience:
- Dissociative effects — feeling detached from surroundings (this is expected and monitored)
- Nausea — can be managed with anti-nausea medication
- Elevated blood pressure — monitored throughout the session
- Drowsiness — patients should not drive after sessions
All sessions are conducted under medical supervision with continuous monitoring.
Insurance & Cost
Standard TMS protocols are covered by most major insurance plans, including Medicare. We handle prior authorization and work directly with your insurance.
Accelerated TMS protocols (2-week) may also be covered as they use FDA-cleared devices and established session counts.
Intensive TMS protocols (5-day and 1-day) are typically not covered by insurance and are self-pay.
Ketamine/KAP is generally not covered by insurance, though Spravato (esketamine nasal spray) may be covered for some patients. Contact us for pricing information.
Ready to learn more?
Take our quick assessment to see if TMS or KAP might be right for your situation, or contact our care team directly.